Carcinoma Of Thyroid — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for carcinoma of thyroid. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
2
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Carcinoma Of Thyroid

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sanofi 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating carcinoma of thyroid. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Caprelsa
VANDETANIB
 Sanofi 2 60 — 2028-08-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8067427 Caprelsa formulation 60 2028-08-08
8067427 Caprelsa formulation 60 2028-08-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8067427 Caprelsa formulation 60 2028-08-08
8067427 Caprelsa formulation 60 2028-08-08

Related